Here is a blog I wrote about why I feel MRD negativity should be used as a surrogate endpoint in #myeloma clinical trials. MRD as a Clinical Trial Endpoint: A Patient Perspective healthtree.org/myeloma/commun… #MMSM
@MyelomaTeacher Thank you for your essay. Question for you— for new therapeutics treating myeloma, the FDA can already give accelerated approval based on response rate. How does MRD help get additional new drugs to market faster than response rate?
@MyelomaTeacher 100% agree. 1 more point... How can we cure MM if we're exclusively concerned with duration of response? Accepting MRD-negativity as a legitimate RCT endpoint incentivizes finding a cure through improved depth of response. #MeltTheWholeIceberg
@MyelomaTeacher Wow . Nice essay and very true.
@MyelomaTeacher @MyelomaValarie Excellent read! Couldn’t agree more with you Cindy.
@MyelomaTeacher I love this quote from you; Gone is the era of paternalistic medicine. Involve patients in shared decision making, after all this is our life. We should be the ones that weigh the risks and benefits of a new therapy (including the potential of life-changing unknown risks)
@MyelomaTeacher I really do love what is written here! An excellent perspective that should have all of us accelerate our push for a cure. Thank you!